T
Thomas Wiesner
Researcher at Medical University of Vienna
Publications - 76
Citations - 7028
Thomas Wiesner is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Melanoma & Nevus. The author has an hindex of 34, co-authored 73 publications receiving 5816 citations. Previous affiliations of Thomas Wiesner include University of Graz & Memorial Sloan Kettering Cancer Center.
Papers
More filters
Journal ArticleDOI
Mutations in GNA11 in Uveal Melanoma
Catherine D. Van Raamsdonk,Klaus G. Griewank,Michelle B. Crosby,Maria C. Garrido,Swapna S. Vemula,Thomas Wiesner,Anna C. Obenauf,Werner Wackernagel,Gary G. R. Green,Nancy Bouvier,M. Mert Sozen,Gail Baimukanova,Ritu Roy,Adriana Heguy,Igor Dolgalev,Raya Khanin,Klaus J. Busam,Michael R. Speicher,Joan M. O'Brien,Boris C. Bastian +19 more
TL;DR: Constitutive activation of the pathway involving these two genes appears to be a major contributor to the development of uveal melanoma.
Journal ArticleDOI
Germline mutations in BAP1 predispose to melanocytic tumors
Thomas Wiesner,Anna C. Obenauf,Anna C. Obenauf,Rajmohan Murali,Isabella Fried,Klaus G. Griewank,Peter Ulz,Christian Windpassinger,Werner Wackernagel,Shea Loy,Ingrid H. Wolf,Agnes Viale,Alex E. Lash,Mono Pirun,Nicholas D. Socci,Arno Rütten,Gabriele Palmedo,David H. Abramson,Kenneth Offit,Arthur Ott,Jürgen C. Becker,Lorenzo Cerroni,Heinz Kutzner,Boris C. Bastian,Michael R. Speicher +24 more
TL;DR: Two families with a new autosomal dominant syndrome characterized by multiple, skin-colored, elevated melanocytic tumors are described, suggesting that loss of BAP1 is associated with a clinically and morphologically distinct type of melanocytics neoplasm.
Journal ArticleDOI
Kinase fusions are frequent in Spitz tumours and spitzoid melanomas.
Thomas Wiesner,Jie He,Roman Yelensky,Rosaura Esteve-Puig,Thomas Botton,Iwei Yeh,Doron Lipson,Geoff Otto,Kristina W. Brennan,Rajmohan Murali,Maria C. Garrido,Vincent A. Miller,Jeffrey S. Ross,Michael F. Berger,Alyssa J. Sparatta,Gabriele Palmedo,Lorenzo Cerroni,Klaus J. Busam,Heinz Kutzner,Maureen T. Cronin,Philip J. Stephens,Boris C. Bastian,Boris C. Bastian +22 more
TL;DR: It is shown that spitzoid neoplasms harbour kinase fusions of ROS1 (17%), NTRK1 (16%), ALK (10%), BRAF (5%) and RET (3%) in a mutually exclusive pattern and may serve as therapeutic targets for metastatic spitzoids melanomas.
Journal ArticleDOI
PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors
William Lee,Sewit Teckie,Thomas Wiesner,Leili Ran,Carlos N. Prieto Granada,Mingyan Lin,Sinan Zhu,Zhen Cao,Yupu Liang,Andrea Sboner,William D. Tap,Jonathan A. Fletcher,Kety Huberman,Li-Xuan Qin,Agnes Viale,Samuel Singer,Deyou Zheng,Michael F. Berger,Yu Chen,Cristina R. Antonescu,Ping Chi +20 more
TL;DR: The highly recurrent and specific inactivation of PRC2 components, NF1 and CDKN2A highlights their critical and potentially cooperative roles in MPNST pathogenesis.
Journal ArticleDOI
Therapy-induced tumour secretomes promote resistance and tumour progression
Anna C. Obenauf,Yilong Zou,Andrew L. Ji,Sakari Vanharanta,Weiping Shu,Hubing Shi,Xiangju Kong,M Bosenberg,Thomas Wiesner,Neal Rosen,Roger S. Lo,Joan Massagué +11 more
TL;DR: Targeted therapy with BRAF, ALK or EGFR kinase inhibitors induces a complex network of secreted signals in drug-stressed human and mouse melanoma and human lung adenocarcinoma cells, which stimulates the outgrowth, dissemination and metastasis of drug-resistant cancer cell clones and supports the survival ofdrug-sensitive cancer cells.